title: Detection of Bacillus anthracis DNA by LightCycler PCR.
abstract: Anthrax is a zoonotic disease that is also well recognized as a potential agent of bioterrorism. Routine culture and biochemical testing methods are useful for the identification of Bacillus anthracis, but a definitive identification may take 24 to 48 h or longer and may require that specimens be referred to another laboratory. Virulent isolates of B. anthracis contain two plasmids (pX01 and pX02) with unique targets that allow the rapid and specific identification of B. anthracis by PCR. We developed a rapid-cycle real-time PCR detection assay for B. anthracis that utilizes the LightCycler instrument (LightCycler Bacillus anthracis kit; Roche Applied Science, Indianapolis, Ind.). PCR primers and probes were designed to identify gene sequences specific for both the protective antigen (plasmid pX01) and the encapsulation B protein (plasmid pX02). The assays (amplification and probe confirmation) can be completed in less than 1 h. The gene encoding the protective antigen (pagA) was detected in 29 of 29 virulent B. anthracis strains, and the gene encoding the capsular protein B (capB) was detected in 28 of 29 of the same strains. Three avirulent strains containing only pX01 or pX02, and therefore only pagA or pagB genes, could be detected and differentiated from virulent strains. The assays were specific for B. anthracis: the results were negative for 57 bacterial strains representing a broad range of organisms, including Bacillus species other than anthracis (n = 31) and other non-Bacillus species (n = 26). The analytical sensitivity demonstrated with target DNA cloned into control plasmids was 1 copy per microl of sample. The LightCycler Bacillus anthracis assay appears to be a suitable method for rapid identification of cultured isolates of B. anthracis. Additional clinical studies are required to determine the usefulness of this test for the rapid identification of B. anthracis directly from human specimens.
authors.affiliation: Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: Constance A
authors.initials: CA
authors.lastname: Bell
authors.forename: James R
authors.initials: JR
authors.lastname: Uhl
authors.forename: Ted L
authors.initials: TL
authors.lastname: Hadfield
authors.forename: John C
authors.initials: JC
authors.lastname: David
authors.forename: Richard F
authors.initials: RF
authors.lastname: Meyer
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Smith
authors.forename: Franklin R
authors.initials: FR
authors.lastname: Cockerill
mesh_terms: D000942:Antigens, Bacterial; D001408:Bacillus anthracis / Q000302:isolation & purification* / Q000472:pathogenicity; D001426:Bacterial Proteins / Q000235:genetics* / Q000378:metabolism; D001427:Bacterial Toxins / Q000235:genetics* / Q000378:metabolism; D004269:DNA, Bacterial / Q000032:analysis*; D006801:Humans; D010957:Plasmids; D016133:Polymerase Chain Reaction / Q000295:instrumentation / Q000379:methods*; D013997:Time Factors; D014774:Virulence / Q000235:genetics
chemical_list: D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D004269:DNA, Bacterial; C030325:anthrax toxin